Alhemo® (concizumab) Rebalancing Agent Approved

A second anti-TFPI rebalancing reagent, Novo Nordisk’s Alhemo® (concizumab), which we described in our 7/24/2024 post, earned FDA approval on 12/20/2024. Concizumab is approved for hemophilia A and B patients with inhibitors. Alhemo joins Pfizer’s anti-TFPI Hympavsi rebalancing agent, which was approved in October 2024. We anticipate a third rebalancing agent, fitusiran, currently in clinical trials, in 2025. Thanks to Ali Sadeghi-Khomami, PhD, Precision BioLogic Inc. scientist, for the heads-up.